[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bariatric-endoscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bariatric-endoscopy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100638169","phase-2-bariatric-endoscopic-antral-myotomy-combined-with-fundal-gastric-mucosal-ablation-100638169",false,"NCT07612527","Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation","Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation for The Management of Obesity","Inclusion Criteria:\n\nBody mass index (BMI) of ≥ 30 kg\u002Fm2 up to 40 kg\u002Fm2. BMI of 27.0 to 29.9 kg\u002Fm2 will be included on the condition of the presence of at least 1 obesity-related comorbidity (Indications based according to the American and European societies for bariatric endoscopy guidelines)\n\nExclusion Criteria:\n\n* Subjects with any previous surgeries to the stomach\n* Any previous bariatric procedures\n* Any current medications for the management of obesity (must be stopped at least 3 months before recruitment)\n* Evidence of severe gastritis, gastric peptic ulcer, or gastric cancer\n* Coagulopathy\n* Pregnancy","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The gastric fundus regulates appetite through orexigenic ghrelin-mediated and anorexigenic visceroceptive pathways. Accordingly, endoscopic gastric fundal mucosal ablation (GFMA) may benefit patients with obesity. Ablation not only affects these mechanisms, but similar to what happens after mucosal ablation for other indications (e.g. ESD for tumor removal), it is expected to cause shrinking of the fundus and reduce gastric volume.\n\nAnother potential target to achieve weight loss is gastric emptying. This is a critical step in digestion that has been found to be more rapid after prolonged exposure to a high-fat diet in both animal and human studies, with rapid emptying also being more common in young people with obesity in some studies. The bariatric endoscopic antral myotomy (BEAM) procedure has been shown to consistently delay gastric emptying without triggering symptoms of gastroparesis and to produce substantial weight loss.\n\nBoth GFMA and BEAM procedures have the advantages of being minimally invasive, performed completely endoscopic and less costly than surgical alternatives or other known endoscopic techniques like intragastric balloon or endoscopic sleeve gastroplasty.",[26,27],"Obesity & Overweight","Bariatric Endoscopy","RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":29,"type":32},{"date":35,"type":20},"2027-12",{"name":37,"class":38},"Cairo University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100333811","prospective-evaluation-of-the-efficacy-and-safety-of-endoscopic-tissue-apposition-100333811","NCT03626194","Prospective Evaluation of the Efficacy and Safety of Endoscopic Tissue Apposition","Inclusion Criteria:\n\n* Patients\\>18 years of age undergoing endoscopy for any of the following indications:\n\nIndications for Tissue Apposition:\n\n* Closure of perforations\n* Closure of full thickness defects created during endoscopic full thickness resection\n* Closure of defects after endoscopic submucosal dissection and endoscopic mucosal resection\n* Closure of mucosotomy after Peroral Endoscopic Myotomy (POEM)\n* Stent fixation\n* Closure of fistulas\n* Natural Orifice Transluminal Endoscopic Surgery defect closures\n* Post-bariatric surgery gastrojejunal anastomosis and gastric pouch revision (transoral outlet repair)\n* Primary endoscopic sleeve gastroplasty\n\nExclusion Criteria:\n\n* Patients unable or unwilling to provide consent\n* Pregnant patients\n* Coagulation disorders (INR \\>1.8, platelet \\\u003C50,000)\n* GI Bleeding\n* Hemodynamic instability\n* Enrollment in another device or drug study that may confound the results","89 Years",{"count":48,"type":20},500,"2 Years","OBSERVATIONAL","This study is a prospective registry of patients undergoing endoscopic suturing and\u002For clip placement at our institution to assess the efficacy and safety of endoscopic tissue apposition.\n\n1.1 Hypothesis: Endoscopic tissue apposition is efficacious and safe in the practice of gastrointestinal endoscopy.\n\n1.2 Aims: To prospectively evaluate the efficacy and safety of Endoscopic Tissue Apposition in the practice of gastrointestinal endoscopy.",[53,54,55,27,56,57],"Endoscopic Tissue Apposition","Endoscopic Suturing","Endoscopic Clipping","Transoral Outlet Reduction","Endoscopic Sleeve Gastroplasty","2024-05-20",{"date":60,"type":32},"2024-05-21",{"date":62,"type":32},"2016-12-12",{"date":64,"type":20},"2026-12-16",{"name":66,"class":38},"University of Colorado, Denver"]